Naveena Singh1, C Blake Gilks2, Nafisa Wilkinson3, W Glenn McCluggage4. 1. Department of Cellular Pathology, Barts Health NHS Trust, London, UK. 2. Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada. 3. Department of Histopathology, St James's Hospital, Leeds, UK. 4. Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK.
Abstract
AIMS: The available evidence indicates that most non-uterine high-grade serous carcinomas (HGSCs) arise from the fallopian tube (FT), but approaches to primary site assignment have not evolved to reflect this. The aim of this study was to assess the application of recently proposed criteria for site assignment. METHODS AND RESULTS: One hundred and fifty-one HGSCs from four centres were reviewed retrospectively. Sixty-three of 80 (79%) chemonaive (CN) and 45 of 71 (68%) post-neoadjuvant chemotherapy (NACT) cases were assigned as FT primaries with the new criteria, whereas 58 of 80 (73%) and 45 of 71 (63%) were assigned as ovarian primaries with traditional criteria (P < 0.0001). Of 111 prospectively collected HGSCs, with consistent detailed fimbrial examination, 44 of 53 (83%) CN and 44 of 58 (76%) NACT cases were assigned as FT primaries. The reproducibility of site assignment was tested in a subset of 50 cases: all four reviewing pathologists agreed on the primary site in 48 of 50 (96%) cases, and three of four agreed in 49 of 50 (98%) cases. Of the 53 prospectively studied CN cases, bilateral ovarian involvement (62%) was significantly more frequent than bilateral tubal involvement (12%, P < 0.0001), further supporting a tubal origin and ovarian metastasis in most cases. CONCLUSIONS: With currently accepted protocols, the proposed guidelines are easy to apply and result in consistent site assignment in non-uterine HGSCs. Most cases of non-uterine HGSC were considered to be primary FT neoplasms.
AIMS: The available evidence indicates that most non-uterine high-grade serous carcinomas (HGSCs) arise from the fallopian tube (FT), but approaches to primary site assignment have not evolved to reflect this. The aim of this study was to assess the application of recently proposed criteria for site assignment. METHODS AND RESULTS: One hundred and fifty-one HGSCs from four centres were reviewed retrospectively. Sixty-three of 80 (79%) chemonaive (CN) and 45 of 71 (68%) post-neoadjuvant chemotherapy (NACT) cases were assigned as FT primaries with the new criteria, whereas 58 of 80 (73%) and 45 of 71 (63%) were assigned as ovarian primaries with traditional criteria (P < 0.0001). Of 111 prospectively collected HGSCs, with consistent detailed fimbrial examination, 44 of 53 (83%) CN and 44 of 58 (76%) NACT cases were assigned as FT primaries. The reproducibility of site assignment was tested in a subset of 50 cases: all four reviewing pathologists agreed on the primary site in 48 of 50 (96%) cases, and three of four agreed in 49 of 50 (98%) cases. Of the 53 prospectively studied CN cases, bilateral ovarian involvement (62%) was significantly more frequent than bilateral tubal involvement (12%, P < 0.0001), further supporting a tubal origin and ovarian metastasis in most cases. CONCLUSIONS: With currently accepted protocols, the proposed guidelines are easy to apply and result in consistent site assignment in non-uterine HGSCs. Most cases of non-uterine HGSC were considered to be primary FT neoplasms.
Authors: Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman Journal: Nat Rev Cancer Date: 2016-11-25 Impact factor: 60.716
Authors: Gillian E Hanley; Jin Niu; Jihee Han; Sharon Fung; Heather Bryant; Janice S Kwon; David G Huntsman; Sarah J Finlayson; Jessica N McAlpine; Dianne Miller; Craig C Earle Journal: CMAJ Open Date: 2022-05-31
Authors: Jatinderpal K Kalsi; Andy Ryan; Aleksandra Gentry-Maharaj; Danielle Margolin-Crump; Naveena Singh; Matthew Burnell; Elizabeth Benjamin; Sophia Apostolidou; Mariam Habib; Susan Massingham; Chloe Karpinskyj; Robert Woolas; Martin Widschwendter; Lesley Fallowfield; Stuart Campbell; Steven Skates; Alistair McGuire; Max Parmar; Ian Jacobs; Usha Menon Journal: Trials Date: 2021-01-25 Impact factor: 2.279
Authors: Brittney S Harrington; Yaowu He; Claire M Davies; Sarah J Wallace; Mark N Adams; Elizabeth A Beaven; Deborah K Roche; Catherine Kennedy; Naven P Chetty; Alexander J Crandon; Christopher Flatley; Niara B Oliveira; Catherine M Shannon; Anna deFazio; Anna V Tinker; C Blake Gilks; Brian Gabrielli; Donal J Brennan; Jermaine I Coward; Jane E Armes; Lewis C Perrin; John D Hooper Journal: Br J Cancer Date: 2016-02-04 Impact factor: 7.640